← Library
A cosmetic ingredient, not regulated or approved as a drug. This page is educational information only, not medical advice.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

sh-Oligopeptide-1

Cosmetic ingredient

Cosmetic growth factor peptide

Also known as: EGF, epidermal growth factor, oligopeptide-1, rh-EGF, RH-OLIGOPEPTIDE-1

Evidence score
41/ 100
Emerging evidence

Early evidence, mostly unproven in humans

  • Regulatory standing. Cosmetic ingredient, not regulated as a drug
  • Limited human data. Some human data exists, not conclusive
  • Registered human trials. 2 registered studies on ClinicalTrials.gov
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

sh-Oligopeptide-1 is the cosmetic ingredient name for a lab-made (recombinant) version of human epidermal growth factor, a 53 amino acid protein that signals skin cells through the EGF receptor. In skin care it is included with the idea that it may support cell turnover and skin repair when applied to the skin.

What the evidence shows

Automatic summaryLimited human data

It is regulated as a cosmetic ingredient and is not FDA-approved for any medical use. Human evidence specific to this ingredient is thin, with only 2 registered trials and a few published papers, so benefits for skin appearance or healing have not been clearly established.

Key facts

Molecular formula
C270H401N73O83S7
Molecular weight
6222 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

2registered studies
Nonemost advanced phase
2completed (sample)
0recruiting (sample)

Investigation on a Topical Cosmetic Pain Lotion (Egyfil) for Stiffness and Pain Relief

CompletedNCT05711953

Efficacy Study of a Repairing Cream in Atopic Dermatitis

CompletedNCT07742241

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

3papers referencing sh-Oligopeptide-1

A pre-market interventional, single-arm clinical investigation of a new topical lotion based on hyaluronic acid and peptides, EGYFIL<sup>TM</sup>, for the treatment of pain and stiffness in soft tissues.

BMC Musculoskelet Disord2023

Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud?

Cutan Ocul Toxicol2023

Update on the Research of an Emulgel for the Effective Treatment of Atopic Dermatitis: Clinical Investigation in Children.

Gels2025

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.